An Interesting Read for Anyone with both JAK2 and TET2 Mutations

[Trueblue8]

I have ET with both JAK2 and TET2 mutations and I found this link very informative as it's explained simply!

bloodcancer.org.uk/news/how...

Ian

[Rachelthepotter]

Thanks, Ian. Very helpful.

Rachel

[Ipadlin]

Thanks, this is a good article to share with people who know of my diagnosis. Good too to know that research is moving forward in this way.

[Bluetop]

Thanks for posting! I am awaiting results of a gene panel test.

[Solyesh]

Thanks! Have ET with Jak2 and TET2 - gene panel testing indicates a rather high (pre-Peg) Jak2 burden but almost non-existent TET2 reading (2-4%) which at the time my MPN specialist said was "good news" - hopefully a full gene panel will start to be standard of care for MPNs..we need as much information/data as possible to continue progressing therapies/medicines.

[Janis12]

Hi thanks for posting this link, very interesting. I have Tet 2 only....it's a mine field.

[Wildwood6]

Very interesting. I have PMF with CALR and TET2. I wonder if the research looked at CALR as well as JAK2 mutations.

[EPguy]

Neat new info. It seems not specific to TET2, while TET2 was used to get the theory started. They found "Three ... genes that were identified", TET2 must be one of the 3 genes or "added factors" as it could be called.

An implication of the report is insight to the known action of IFN to reduce the Jak2 mutation, and maybe Rux also. IFN is known to deplete the mutation by exhaustion of the mutant cells. This report finds Jak2 naturally exhausts on its own. (Absent the added factor)"the population of JAK2 mutated cells would simply divide quickly and then die out."

It could be IFN acts more directly on one or more of these (added factors) for allele reduction rather than on Jak2. This would be new info to the IFN experts I believe and might be another way to track IFN and/or Rux effects.

Best case as always that this report may help boost would be better targeted therapies with fewer side effects, as I know too well.